A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.

B. J. M. Braakhuis, G. J. Peters, C. M. Kuiper, G. Veerman, V. W. T. Ruiz Van Haperen, A. M. Bergman, Interaction between cisplatin and gemcitabine in vitro and in vivo. Seminars in Oncology. ,vol. 22, pp. 72- 79 ,(1995)

Paul A. Bunn, Karen Kelly, New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clinical Cancer Research. ,vol. 4, pp. 1087- 1100 ,(1998)

H Anderson, B Lund, F Bach, N Thatcher, J Walling, H H Hansen, Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 12, pp. 1821- 1826 ,(1994) , 10.1200/JCO.1994.12.9.1821

M Fukuoka, H Niitani, A Suzuki, M Motomiya, K Hasegawa, Y Nishiwaki, T Kuriyama, Y Ariyoshi, S Negoro, N Masuda, A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 10, pp. 16- 20 ,(1992) , 10.1200/JCO.1992.10.1.16

H Kunitoh, K Watanabe, T Onoshi, K Furuse, H Niitani, T Taguchi, Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer : A Japanese cooperative study Journal of Clinical Oncology. ,vol. 14, pp. 1649- 1655 ,(1996) , 10.1200/JCO.1996.14.5.1649

Kiyoshi Mori, Hiroyuki Kobayashi, Yukari Kamiyama, Yasuhiko Kano, Tetsuro Kodama, A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer Cancer Chemotherapy and Pharmacology. ,vol. 64, pp. 73- 78 ,(2009) , 10.1007/S00280-008-0846-Z

Kiyoshi Komuta, Tadashi Osaki, Masahide Mori, Soichiro Yokota, Yoshiro Tanio, Kaoru Matsui, Fumio Imamura, Ichiro Kawase, A phase II study directed by a clinical pathway for carboplatin and weekly paclitaxel in previously untreated patients with unresectable non-small cell lung cancer. Chemotherapy. ,vol. 56, pp. 39- 45 ,(2010) , 10.1159/000287355

Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Vı́tězslav Kolek, Jana Skřičková, Miloš Pešek, Hana Fojtů, Ivona Grygárková, Dimka Sixtová, Jaromı́r Roubec, Eva Hořenková, Libor Havel, Petr Průša, Leona Nováková, Tomáš Skácel, Milan Kůta, Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. ,vol. 41, pp. 321- 331 ,(2003) , 10.1016/S0169-5002(03)00233-2

Fu-Tsai Chung, Kang-Yun Lee, Yueh-Fu Fang, Meng-Heng Shieh, Shu-Min Lin, Chih-Teng Yu, Yun-Lun Lo, Ting-Yu Lin, Chih-Hsi Kuo, Po-Hao Feng, Yung-Lun Ni, Han-Pin Kuo, Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer Chemotherapy. ,vol. 57, pp. 147- 155 ,(2011) , 10.1159/000321037

Gregory A. Masters, Athanassios E. Argiris, Elizabeth A. Hahn, J Thaddeus Beck, P Gregory Rausch, Zhishen Ye, Matthew J. Monberg, Leslie P. Bloss, Rafael E. Curiel, Coleman K. Obasaju, A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Journal of Thoracic Oncology. ,vol. 1, pp. 19- 24 ,(2006) , 10.1097/01243894-200601000-00006